Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GCLLSG 2016 | Tsunami of evidence in CLL

Clemens Wendtner • 16 Sep 2016
GCLLSG 2016
Chronic Lymphocytic Leukemia

Clemens Wendtner, MD of Klinikum Schwabing, Munich, Germany, highlights key advances in the field of chronic lymphocytic leukemia (CLL) discussed at the German CLL Study Group (GCLLSG) 2016 meeting. Dr Wendtner mentions the importance of subclones in CLL, new kinase inhibitor combinations, and immunotherapy. Using checkpoint inhibitors combined with immunostimulatory drugs may be a new avenue in CLL research. Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.

More from Clemens Wendtner

0:56
How can doctors discuss CLL treatment options with patients?
Clemens Wendtner • 27 Mar 2017
1:17
What are the genetic and environmental risk factors for chronic lymphoblastic leukemia (CLL)?
Clemens Wendtner • 27 Mar 2017
1:27
Current and future CLL diagnostic tools
Clemens Wendtner • 27 Mar 2017
1:39
Overview of the CLLR3 trial of obinutuzumab
Clemens Wendtner • 16 Sep 2016

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals